Total Payments
$80,327
2024 Payments
$11,153
Companies
64
Transactions
470
Medicare Patients
1,962
Medicare Billing
$368,849
Payment Breakdown by Category
Other$34,953 (43.5%)
Consulting$22,344 (27.8%)
Food & Beverage$14,462 (18.0%)
Travel$7,789 (9.7%)
Education$735.07 (0.9%)
Research$44.41 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,255 | 12 | 42.6% |
| Consulting Fee | $22,344 | 11 | 27.8% |
| Food and Beverage | $14,462 | 404 | 18.0% |
| Travel and Lodging | $7,789 | 20 | 9.7% |
| Education | $735.07 | 15 | 0.9% |
| Long term medical supply or device loan | $697.90 | 7 | 0.9% |
| Unspecified | $44.41 | 1 | 0.1% |
Payments by Type
General
$80,283
469 transactions
Research
$44.41
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $40,478 | 43 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,349 | 27 | $0 (2024) |
| EMD Serono, Inc. | $4,448 | 7 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $3,916 | 4 | $0 (2024) |
| SpringWorks Therapeutics, Inc. | $2,893 | 7 | $0 (2024) |
| Incyte Corporation | $2,829 | 17 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $2,082 | 5 | $0 (2024) |
| Daiichi Sankyo Inc. | $1,934 | 10 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $1,922 | 3 | $0 (2024) |
| Tempus AI, Inc | $1,500 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,153 | 171 | SpringWorks Therapeutics, Inc. ($2,893) |
| 2023 | $11,862 | 146 | AstraZeneca Pharmaceuticals LP ($4,465) |
| 2022 | $3,312 | 41 | Daiichi Sankyo Inc. ($1,713) |
| 2021 | $2,379 | 10 | Taiho Oncology, Inc. ($1,650) |
| 2020 | $2,456 | 9 | Incyte Corporation ($1,845) |
| 2019 | $6,707 | 23 | Genentech USA, Inc. ($5,479) |
| 2018 | $6,758 | 19 | Genentech USA, Inc. ($5,781) |
| 2017 | $35,701 | 51 | Genentech USA, Inc. ($29,062) |
All Payment Transactions
470 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Oncology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $18.37 | General |
| Category: Oncology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $0.30 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $26.05 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $121.78 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Exelixis Inc. | — | Education | In-kind items and services | $89.99 | General |
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: DESMOID TUMORS | ||||||
| 11/18/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 11/11/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $7.55 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: Rare Disease | ||||||
| 11/05/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $102.96 | General |
| 11/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $31.05 | General |
| Category: Oncology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: Oncology | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.01 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TAS-120 | Taiho Oncology, Inc. | $44.41 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 460 | 1,054 | $213,447 | $90,273 |
| 2022 | 5 | 531 | 1,187 | $230,784 | $98,941 |
| 2021 | 5 | 510 | 1,131 | $239,180 | $105,059 |
| 2020 | 5 | 461 | 1,138 | $206,704 | $74,576 |
Total Patients
1,962
Total Services
4,510
Medicare Billing
$368,849
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 485 | $102,383 | $42,113 | 41.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 100 | 245 | $38,814 | $17,355 | 44.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 80 | 157 | $34,991 | $16,533 | 47.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 48 | $13,741 | $5,387 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 83 | $12,096 | $4,519 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $4,530 | $1,862 | 41.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $3,796 | $1,298 | 34.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $3,096 | $1,206 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 149 | 498 | $103,870 | $44,575 | 42.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 107 | 294 | $45,864 | $20,515 | 44.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 80 | 127 | $27,686 | $13,139 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 78 | 137 | $19,728 | $7,499 | 38.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $12,559 | $4,292 | 34.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 32 | $8,929 | $4,210 | 47.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $5,994 | $2,099 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 13 | 13 | $3,354 | $1,337 | 39.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 28 | $2,800 | $1,274 | 45.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 168 | 521 | $108,836 | $45,726 | 42.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 90 | 237 | $37,025 | $17,192 | 46.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 73 | 135 | $29,430 | $15,061 | 51.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 56 | 81 | $22,698 | $10,535 | 46.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 35 | 35 | $14,068 | $5,625 | 40.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 35 | 35 | $11,655 | $4,561 | 39.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 42 | $8,988 | $3,327 | 37.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 42 | 45 | $6,480 | $3,031 | 46.8% |
About Dr. Ki Chung, MD
Dr. Ki Chung, MD is a Hematology & Oncology healthcare provider based in Spartanburg, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336110113.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ki Chung, MD has received a total of $80,327 in payments from pharmaceutical and medical device companies, with $11,153 received in 2024. These payments were reported across 470 transactions from 64 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($34,255).
As a Medicare-enrolled provider, Chung has provided services to 1,962 Medicare beneficiaries, totaling 4,510 services with total Medicare billing of $368,849. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Spartanburg, SC
- Active Since 01/30/2006
- Last Updated 01/31/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336110113
Products in Payments
- Avastin (Biological) $40,318
- IMFINZI (Biological) $4,502
- Bavencio (Biological) $4,416
- OGSIVEO (Drug) $2,893
- LONSURF (Drug) $2,222
- Onivyde (Drug) $1,747
- ENHERTU (Drug) $1,713
- Lonsurf (Drug) $1,650
- Stivarga (Drug) $1,114
- KEYTRUDA (Biological) $994.05
- KISQALI (Drug) $827.02
- IMBRUVICA (Drug) $425.77
- ALIYA SYSTEM (Device) $365.60
- TAGRISSO (Drug) $311.92
- Lenvima (Drug) $288.36
- BRUKINSA (Drug) $285.45
- Venclexta (Drug) $281.16
- ADCETRIS (Biological) $243.85
- IBRANCE (Drug) $237.86
- Yescarta (Drug) $230.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Spartanburg
Dr. Steven Corso, Md, MD
Hematology & Oncology — Payments: $14,183
Hematology & Oncology $14,183
James Bearden, Md, MD
Hematology & Oncology — Payments: $12,982
Hematology & Oncology $12,982
Dr. Kim Hont Yee, Md, MD
Hematology & Oncology — Payments: $12,245
Hematology & Oncology $12,245
Dr. Abderrahim Khomani, M.d, M.D
Hematology & Oncology — Payments: $9,748
Hematology & Oncology $9,748
Mr. Leonard Schutz, Md, Facp, MD, FACP
Hematology & Oncology — Payments: $4,746
Hematology & Oncology $4,746
Dr. Samuel Adediran, M.d.,, M.D.,
Hematology & Oncology — Payments: $3,434
Hematology & Oncology $3,434